FORM OF INDEMNITY AGREEMENTIndemnity Agreement • May 1st, 2018 • Retrophin, Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNITY AGREEMENT (this “Agreement”) dated as of _________________, 20___, is made and entered into by and between RETROPHIN, INC., a Delaware corporation (the “Company”), and ___________________ (“Indemnitee”).
EMPLOYMENT AGREEMENTEmployment Agreement • May 1st, 2018 • Retrophin, Inc. • Pharmaceutical preparations • California
THIS EMPLOYMENT AGREEMENT is effective as of the last date signed by the parties hereto (the “Effective Date”) and is entered into by and between Retrophin, Inc., a Delaware corporation (hereinafter the “Company”), and William Rote (hereinafter “Executive”).
AMENDMENT NO. 5 TO SUBLICENSE AGREEMENTSublicense Agreement • May 1st, 2018 • Retrophin, Inc. • Pharmaceutical preparations • New York
THIS AMENDMENT NO. 5 TO SUBLICENSE AGREEMENT (the “Amendment”) is made and entered into as of March 20, 2018 (“Amendment Effective Date”) and amends the Sublicense Agreement effective as of February 16, 2012, as amended pursuant to that certain Amendment to Sublicense Agreement dated December 11, 2012, Amendment No. 2 to Sublicense Agreement dated January 7, 2013, Amendment No. 3 to Sublicense Agreement dated February 27, 2015 and Amendment No. 4 to Sublicense Agreement dated September 17, 2015 (the “Sublicense Agreement”) by and between Ligand Pharmaceuticals Incorporated, a corporation organized under the laws of Delaware and having a place of business at 3911 Sorrento Valley Boulevard, Suite 110, San Diego, CA 92121 and its wholly owned subsidiary, Pharmacopeia, LLC (as successor in interest to Pharmacopeia Drug Discovery Inc.) (“PCOP”), a limited liability company organized under the laws of Delaware and having a place of business at 3911 Sorrento Valley Boulevard, Suite 110, San D
